Literature DB >> 10844025

Chronic heroin self-administration desensitizes mu opioid receptor-activated G-proteins in specific regions of rat brain.

L J Sim-Selley1, D E Selley, L J Vogt, S R Childers, T J Martin.   

Abstract

In previous studies from our laboratory, chronic noncontingent morphine administration decreased mu opioid receptor-activated G-proteins in specific brainstem nuclei. In the present study, mu opioid receptor binding and receptor-activated G-proteins were examined after chronic heroin self-administration. Rats were trained to self-administer intravenous heroin for up to 39 d, achieving heroin intake up to 366 mg. kg(-1). d(-1). mu opioid-stimulated [(35)S]GTPgammaS and [(3)H]naloxone autoradiography were performed in adjacent brain sections. Agonist-stimulated [(35)S]GTPgammaS autoradiography also examined other G-protein-coupled receptors, including delta opioid, ORL-1, GABA(B), adenosine A(1), cannabinoid, and 5-HT(1A). In brains from heroin self-administering rats, decreased mu opioid-stimulated [(35)S]GTPgammaS binding was observed in periaqueductal gray, locus coeruleus, lateral parabrachial nucleus, and commissural nucleus tractus solitarius, as previously observed in chronic morphine-treated animals. In addition, decreased mu opioid-stimulated [(35)S]GTPgammaS binding was found in thalamus and amygdala after heroin self-administration. Despite this decrease in mu-activated G-proteins, [(3)H]naloxone binding demonstrated increased mu opioid receptor binding in several brain regions after heroin self-administration, and there was a significant decrease in mu receptor G-protein efficiency as expressed as a ratio between agonist-activated G-proteins and mu receptor binding. No effects on agonist-stimulated [(35)S]GTPgammaS binding were found for any other receptor examined. The effect of chronic heroin self-administration to decrease mu-stimulated [(35)S]GTPgammaS binding varied between regions and was highest in brainstem and lowest in the cortex and striatum. These results not only provide potential neuronal mechanisms that may contribute to opioid tolerance and dependence, but also may explain why various chronic effects of opioids develop to different degrees.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10844025      PMCID: PMC6772440     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  51 in total

1.  Morphine-induced desensitization and down-regulation at mu-receptors in 7315C pituitary tumor cells.

Authors:  P S Puttfarcken; B M Cox
Journal:  Life Sci       Date:  1989       Impact factor: 5.037

2.  The mu-opioid receptor down-regulates differently from the delta-opioid receptor: requirement of a high affinity receptor/G protein complex formation.

Authors:  S Chakrabarti; W Yang; P Y Law; H H Loh
Journal:  Mol Pharmacol       Date:  1997-07       Impact factor: 4.436

3.  Signal transduction correlates of mu opioid agonist intrinsic efficacy: receptor-stimulated [35S]GTP gamma S binding in mMOR-CHO cells and rat thalamus.

Authors:  D E Selley; Q Liu; S R Childers
Journal:  J Pharmacol Exp Ther       Date:  1998-05       Impact factor: 4.030

Review 4.  Autoradiographic visualization in brain of receptor-G protein coupling using [35S]GTP gamma S binding.

Authors:  L J Sim; D E Selley; S R Childers
Journal:  Methods Mol Biol       Date:  1997

5.  Conditioned place preference: no tolerance to the rewarding properties of morphine.

Authors:  A Contarino; A Zanotti; F Drago; F Natolino; M Lipartiti; P Giusti
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1997-05       Impact factor: 3.000

6.  Non-competitive nature of the antagonistic mechanism responsible for tolerance development to opiate-induced analgesia.

Authors:  J Bläsig; G Meyer; V Höllt; J Hengstenberg; J Dum; A Herz
Journal:  Neuropharmacology       Date:  1979-05       Impact factor: 5.250

7.  Anatomically distinct opiate receptor fields mediate reward and physical dependence.

Authors:  M A Bozarth; R A Wise
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

8.  Heroin addicts and methadone treatment in Albuquerque: a 22-year follow-up.

Authors:  A Goldstein; J Herrera
Journal:  Drug Alcohol Depend       Date:  1995-12       Impact factor: 4.492

9.  Stimulation of guanosine-5'-O-(3-[35S]thio)triphosphate binding by endogenous opioids acting at a cloned mu receptor.

Authors:  A Alt; A Mansour; H Akil; F Medzihradsky; J R Traynor; J H Woods
Journal:  J Pharmacol Exp Ther       Date:  1998-07       Impact factor: 4.030

10.  Opiate receptor down-regulation and desensitization in neuroblastoma X glioma NG108-15 hybrid cells are two separate cellular adaptation processes.

Authors:  P Y Law; D S Hom; H H Loh
Journal:  Mol Pharmacol       Date:  1983-11       Impact factor: 4.436

View more
  46 in total

1.  Direct administration of ifenprodil and citalopram into the nucleus accumbens inhibits cue-induced nicotine seeking and associated glutamatergic plasticity.

Authors:  Jonna M Leyrer-Jackson; Jose A Piña; Joseph McCallum; M Foster Olive; Cassandra D Gipson
Journal:  Brain Struct Funct       Date:  2020-06-26       Impact factor: 3.270

2.  Brain region-specific mechanisms for acute morphine-induced mitogen-activated protein kinase modulation and distinct patterns of activation during analgesic tolerance and locomotor sensitization.

Authors:  Shoshana Eitan; Camron D Bryant; Nazli Saliminejad; Yu C Yang; Elroy Vojdani; Duane Keith; Roberto Polakiewicz; Christopher J Evans
Journal:  J Neurosci       Date:  2003-09-10       Impact factor: 6.167

Review 3.  Mu opioid receptor regulation and opiate responsiveness.

Authors:  Kirsten M Raehal; Laura M Bohn
Journal:  AAPS J       Date:  2005-10-19       Impact factor: 4.009

Review 4.  Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction.

Authors:  M J Christie
Journal:  Br J Pharmacol       Date:  2008-04-14       Impact factor: 8.739

Review 5.  Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance.

Authors:  Kirsten M Raehal; Cullen L Schmid; Chad E Groer; Laura M Bohn
Journal:  Pharmacol Rev       Date:  2011-08-26       Impact factor: 25.468

6.  Stabilization of morphine tolerance with long-term dosing: association with selective upregulation of mu-opioid receptor splice variant mRNAs.

Authors:  Jin Xu; Andrew J Faskowitz; Grace C Rossi; Mingming Xu; Zhigang Lu; Ying-Xian Pan; Gavril W Pasternak
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-22       Impact factor: 11.205

7.  Region-dependent attenuation of mu opioid receptor-mediated G-protein activation in mouse CNS as a function of morphine tolerance.

Authors:  L J Sim-Selley; K L Scoggins; M P Cassidy; L A Smith; W L Dewey; F L Smith; D E Selley
Journal:  Br J Pharmacol       Date:  2007-06-18       Impact factor: 8.739

Review 8.  Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance.

Authors:  John T Williams; Susan L Ingram; Graeme Henderson; Charles Chavkin; Mark von Zastrow; Stefan Schulz; Thomas Koch; Christopher J Evans; Macdonald J Christie
Journal:  Pharmacol Rev       Date:  2013-01-15       Impact factor: 25.468

Review 9.  Alterations in the levels of heterotrimeric G protein subunits induced by psychostimulants, opiates, barbiturates, and ethanol: Implications for drug dependence, tolerance, and withdrawal.

Authors:  Nobue Kitanaka; Junichi Kitanaka; F Scott Hall; Tomohiro Tatsuta; Yoshio Morita; Motohiko Takemura; Xiao-Bing Wang; George R Uhl
Journal:  Synapse       Date:  2008-09       Impact factor: 2.562

10.  Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity.

Authors:  Jianren Mao; Backil Sung; Ru-Rong Ji; Grewo Lim
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.